•  
  •  
  •  
  •  

2023-03-21 16:59:14

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome

Keywords Selected:  CEAT

Research

  • CEAT - Result Report Q3 FY22 - YES Securities
  • CEAT - 3QFY22 Result Update - Margin Pressure to Continue; Reiterate SELL - Reliance Research
  • CEAT Ltd - Q3FY22 Result First cut - YES Securities

Stock Report

  • Anant Goenka named as the Vice Chairman of CEAT Ltd
  • CEAT Ltd posts consolidated Q3FY23 PAT of Rs. 35.39 crores
  • CEAT Ltd approves investment of Rs. 396 crores on capex
  • CEAT Ltd consolidated Q2FY23 PAT at Rs. 7.83 crores
  • CEAT Limited invests in Taabi Mobility Ltd
  • CEAT posts Rs. 9.25 crores consolidated profit in Q1 FY23
  • CEAT Ltd recommends final dividend of Rs. 3
  • CEAT Ltd consolidated Q4 FY2022 PAT at Rs. 25.25 crores
  • CCI imposes penalty of Rs. 252.16 crore on CEAT Ltd
  • CEAT posts Rs. 20.01 crore consolidated loss in Q3 FY22
  • CEAT Ltd consolidated Q2FY22 net profit climbs QoQ to Rs. 41.98 crore

Latest Post

  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022